Richard Paulson, Karyopharm CEO

An­a­lysts ques­tion Karyophar­m's PhI­II en­dome­tri­al can­cer da­ta as biotech will charge ahead to FDA

Karyopharm Ther­a­peu­tics tout­ed on Tues­day Phase III da­ta for a can­cer pro­gram it de­scribed as pos­i­tive, but which Wall Street viewed in a more neg­a­tive …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.